Mainz
Germany
31
2021-05-06
The entities that hold a legal rights for patent applications filed by inventor Schrattenholz André:
André Schrattenholz from Mainz, DE has applied for patents for these inventions. The list has both pending applications and granted patents:
METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS
#2 | 2021-03-18Method of effecting neuroprotection using soluble neuregulin isoforms
#3 | 2019-10-10Method of effecting neuroprotection using soluble neuregulin isoforms
#4 | 2017-02-09Method of effecting neuroprotection using soluble Neuregulin isoforms
#5 | 2015-08-27ACTIVE SOLUBLE POST-TRANSLATIONALLY MODIFIED NEUREGULIN ISOFORMS
#6 | 2015-03-19NEUREGULIN ISOFORMS, NEUREGULIN POLYPEPTIDES AND USES THEREOF
#7 | 2014-10-30METHOD OF INHIBITING DOPAMINERGIC CELL DEATH
#8 | 2014-09-18PIRENZEPINE AS AN AGENT IN CANCER TREATMENT
#9 | 2014-08-28PHARMACEUTICAL COMPOSITION CONTAINING NEUREGULIN ISOFORMS
#10 | 2014-08-28METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS
#11 | 2013-03-21NEUREGULIN ISOFORMS,NEUREGULIN POLYPEPTIDES AND USES THEREOF
#12 | 2011-12-01PIRENZEPINE AS AN AGENT IN CANCER TREATMENT
#13 | 2011-10-27PIRENZEPINE AS OTOPROTECTIVE AGENT
#14 | 2011-10-06Use of neuregulin-β as an indicator and/or target
#15 | 2011-06-16PROTEIN BIOMARKERS FOR IN VITRO TESTING OF DEVELOPMENTAL TOXICITY AND ENBRYOTOXICITY OF CHEMICAL SUBSTANCES
#16 | 2011-04-28BREAST CANCER PROTEINS
#17 | 2010-11-02Neuregulin-β isoforms associated with neuronal processes
#18 | 2010-10-21Annexin A3 for cancer diagnosis
#19 | 2010-10-07ACTIVE SOLUBLE POST-TRANSLATIONALLY MODIFIED NEUREGULIN ISOFORMS
#20 | 2010-09-30PIRENZEPINE AND DERIVATIVES THEREOF AS ANTI-AMYLOID AGENTS
#21 | 2010-09-16Monoclonal anti-annexin A3 antibodies for the detection of prostate carcinoma
#22 | 2010-05-27Autoimmune regulation of prostate cancer by annexin A3
#23 | 2009-11-19Neuregulin-β isoform
#24 | 2009-07-02Use of finasteride, dutasteride and related compounds for the prevention or treatment of neurologically-associated disorders
#25 | 2009-05-26Use of neuregulin-β as an indicator and/or target
#26 | 2009-03-05Phosphorylated or Non-Phosphorylated MPR as Diagnostic Marker or Therapeutic Target
#27 | 2008-08-21Annexin A3 for prostate cancer diagnosis
#28 | 2007-12-27Enrichment of Enzymatic Cleavage Products
#29 | 2007-11-15Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
#30 | 2007-09-06Muscarinic antagonists with PARP and SIR modulating activity as agents for inflammatory diseases
#31 | 2005-06-16Use of substances for treating tumors
154107 ⎘